Altered Dopamine Metabolism and Response to Treatment with Levodopa/Carbidopa in MCT8 Deficiency
Movement Disorders · 2025
DOI: 10.1002/mds.70093 ↗Kurz gefasst
Fachartikel in der Zeitschrift Movement Disorders, 2025. Verfasst von Fabio Bruschi und 12 weiteren Autor:innen. Beteiligte Einrichtung: Unit of Pediatric Neurology, COALA (Center for Diagnosis and Treatment of Leukodystrophies), V. Buzzi Children's Hospital, Milan, Italy. Hauptthemen laut MEDLINE: Levodopa, Carbidopa, Dopamine, Muscle Hypotonia. Die Arbeit nennt 16 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Background
Allan‐Herndon‐Dudley syndrome (AHDS)/monocarboxylate transporter 8 (MCT8) deficiency is a rare X‐linked encephalopathy caused by SLC16A2 variants, impairing thyroid hormone (TH) transport into the brain. This leads to early central nervous system (CNS) TH deficiency, affecting brain maturation. Dopaminergic circuit involvement is suggested by both pathophysiology and clinical features, reminiscent of infantile parkinsonism.
Objective
This study investigates dopamine metabolism and levodopa/carbidopa response in MCT8 patients.
Methods
We retrospectively and prospectively collected clinical, genetic, and neuroimaging data, performed cerebrospinal fluid (CSF) biogenic amine analyses, and conducted neurological assessments before and after the levodopa trial (10 mg/kg/day).
Results
Ten patients exhibited developmental delay, spasticity, and infantile parkinsonism. CSF analysis showed reduced homovanillic acid in 3/10 patients, with 7/10 in the lowest quartile. Levodopa improved parkinsonism and reactivity in 7/10 patients.
Conclusions
Our findings confirm dopaminergic involvement in AHDS and show that levodopa/carbidopa effectively treats extrapyramidal symptoms. Further investigations could differentiate presynaptic and postsynaptic defects to optimize dopaminergic therapy. © 2025 The Author(s). Movement Disorders published by Wiley Periodicals LLC on behalf of International Parkinson and Movement Disorder Society.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Unit of Pediatric Neurology, COALA (Center for Diagnosis and Treatment of Leukodystrophies), V. Buzzi Children's Hospital, Milan, Italy.
- Department of Biomedical and Clinical Sciences, Università degli Studi di Milano, Milan, Italy.
- Department of Pediatrics, University of Torino, Torino, Italy.
- Department of Clinical and Biological Sciences, University of Torino, Torino, Italy.
- Child and Adolescence Neuropsychiatry Service, Department of Child Pathology and Cure, Regina Margherita Children's Hospital, Turin, Italy.
- Department of Experimental Medicine, Sapienza University of Rome, Rome, Italy.
ORCID-Profile: Fabio Bruschi
Zitieren
APA
Bruschi, F., Vaia, Y., Antonello, C. E., Spada, M., Porta, F., Marinaccio, C., Carducci, C., Opladen, T., Sartorelli, J., Zibordi, F. M., Ghezzi, D., Nicita, F., & Tonduti, D. (2025). Altered Dopamine Metabolism and Response to Treatment with Levodopa/Carbidopa in MCT8 Deficiency. Movement Disorders. https://doi.org/10.1002/mds.70093
Vancouver
Bruschi F, Vaia Y, Antonello CE, Spada M, Porta F, Marinaccio C, et al. Altered Dopamine Metabolism and Response to Treatment with Levodopa/Carbidopa in MCT8 Deficiency. Movement Disorders. 2025. doi:10.1002/mds.70093
BibTeX
@article{Bruschi2025,
author = {Bruschi, Fabio and Vaia, Ylenia and Antonello, Clara E and Spada, Marco and Porta, Francesco and Marinaccio, Cristina and Carducci, Claudia and Opladen, Thomas and Sartorelli, Jacopo and Zibordi, Federica Maria and Ghezzi, Daniele and Nicita, Francesco and Tonduti, Davide},
title = {Altered Dopamine Metabolism and Response to Treatment with Levodopa/Carbidopa in MCT8 Deficiency},
journal = {Movement Disorders},
year = {2025},
doi = {10.1002/mds.70093}
}
EUVIMED